3-propyl-2,3,6,9-tetrahydro-1H-purine-2,6-dione

• ChemBase编号: 703
• 分子式: C8H10N4O2
• 平均质量: 194.1906
• 单一同位素质量: 194.08037558
• SMILES: O=c1n(CCC)c2nc[nH]c2c(=O)[nH]1
• Canonical SMILES: CCCn1c(=O)[nH]c(=O)c2c1nc[nH]2
• InChI: InChI=1S/C8H10N4O2/c1-2-3-12-6-5(9-4-10-6)7(13)11-8(12)14/h4H,2-3H2,1H3,(H,9,10)(H,11,13,14)
• InChIKey: SIQPXVQCUCHWDI-UHFFFAOYSA-N

名称和登记号

名称

• IUPAC标准名: 3-propyl-2,3,6,9-tetrahydro-1H-purine-2,6-dione; 3-propyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione
• IUPAC传统名: 3-propyl-1,9-dihydropurine-2,6-dione; enprofylline; 3-propylxanthine
• 商标名: Nilyph; Oxeze
• 别名: 3-Propylxanthine; Enprofylline; 3-n-PROPYLXANTHINE; 3-n-Propylxanthine; 3-Propylxanthine; Enprofilina [INN-Spanish]; Enprofyllinum [INN-Latin]; Enprofylline

登记号

• CAS号: 41078-02-8
• EC号: 255-201-8
• MDL号: MFCD00043205
• Beilstein号: 1116213
• PubChem SID: 46505790; 24277687; 160964166
• PubChem CID: 1676
• CHEBI ID: 126237
• CHEMBL: 279898
• Chemspider ID: 1613
• DrugBank ID: DB00824
• 美国药典/FDA物质标识码: DT7DT5E518
• 维基百科标题: Enprofylline

理论计算性质

JChem

• Acid pKa: 7.832659
• 质子受体: 3
• 质子供体: 2
• LogD (pH = 5.5): -0.11547689
• LogD (pH = 7.4): -0.23420627
• Log P: -0.11366738
• 摩尔折射率: 49.3104 cm^3
• 极化性: 17.9433 Å^3
• 极化表面积: 78.09 Å^2
• 可自由旋转的化学键: 2
• 里宾斯基五规则: true

ALOGPS 2.1

• Log P: 0.35
• LOG S: -1.53
• 溶解度: 5.68e+00 g/l

分子性质

理化性质

• 溶解度: 1200 mg/L; alcohol: soluble (Solutions should be stored at 4°C.); DMSO: soluble; H2O: slightly soluble (Solutions should be stored at 4°C.)
• 外观: white solid
• 疏水性(logP): -0.2

安全信息

• 保存条件: Room Temperature (15-30°C)
• RTECS编号: UO8439700
• 欧盟危险性物质标志: 有害性(Harmful) (Xn)
• 德国WGK号: 3
• 危险公开号: 20/21/22; R:22
• 安全公开号: 36; S:36/37/39
• GHS危险品标识: GHS07
• GHS警示词: Warning
• GHS危险声明: H302-H312-H332
• GHS警示性声明: P280
• 个人保护装置: dust mask type N95 (US), Eyeshields, Faceshields, Gloves

药理学性质

• 相关基因信息: human ... ADORA1(134), ADORA2A(135), ADORA2B(136), ADORA3(140), PDE4B(5142)mouse ... Adora2b(11541)rat ... Adora1(29290), Adora2a(25369)

产品相关信息

• 纯度: ≥99%

详细说明

MP Biomedicals - 02153779

Weak A1 and A2 adenosine receptor antagonist.

DrugBank - DB00824

• Drug Groups: approved
• Description: Enprofylline is a derivative of theophylline which shares bronchodilator properties. Enprofylline is used in asthma, chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy. Long-term enprofylline administration may be associated with elevation in liver enzyme levels and unpredictable blood levels.
• Indication: Used in the management of symptoms of asthma. Also used in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.
• Pharmacology: Enprofylline is a synthetic dimethylxanthine derivative structurally related to theophylline and caffeine. It antagonizes erythrocyte phosphodiesterase, increasing cAMP activity.
• Affected Organisms: Humans and other mammals
• Absorption: Rapidly absorbed from the digestive tract
• Half Life: 1.9 hours
• Protein Binding: 49%

Sigma Aldrich - P5679

Biochem/physiol Actions
Weak competitive antagonist at both A1 and A2 adenosine receptors.